Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1895 1
1975 1
1992 1
1996 3
1997 1
2001 1
2005 2
2006 4
2007 3
2008 2
2010 2
2011 3
2012 1
2013 3
2014 1
2015 3
2016 3
2017 4
2018 4
2019 4
2021 2
2022 5
2023 3
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

51 results

Results by year

Filters applied: . Clear all
Page 1
Annotated bibliography.
Altman N, Boyer RS, Brunberg JA, Elster AD, George AE, Hackney DB, Lufkin RB, Ross JS, Swartz JD, Weissman JL, Wolpert SM. Altman N, et al. AJNR Am J Neuroradiol. 1996 Oct;17(9):1802-4. AJNR Am J Neuroradiol. 1996. PMID: 8896644 Free PMC article. No abstract available.
In older adults, use of a recombinant zoster vaccine was associated with Guillain-Barré syndrome.
Larson EB, Nelson JC. Larson EB, et al. Ann Intern Med. 2022 Mar;175(3):JC35. doi: 10.7326/J22-0010. Epub 2022 Mar 1. Ann Intern Med. 2022. PMID: 35226533
Goud R, Lufkin B, Duffy J, et al. Risk of Guillain-Barre syndrome following recombinant zoster vaccine in Medicare beneficiaries. ...
Goud R, Lufkin B, Duffy J, et al. Risk of Guillain-Barre syndrome following recombinant zoster vaccine in Medicare beneficiaries. ...
A study on pharmacokinetics, pharmacodynamics and safety of lixisenatide in children and adolescents with type 2 diabetes.
Barrientos-Pérez M, Hsia DS, Sloan L, Nell H, Mungur O, Hovsepian L, Schmider W, Spranger R, Yang N, Niemoeller E. Barrientos-Pérez M, et al. Pediatr Diabetes. 2022 Sep;23(6):641-648. doi: 10.1111/pedi.13343. Epub 2022 Apr 24. Pediatr Diabetes. 2022. PMID: 35411611 Free PMC article. Clinical Trial.

MATERIALS AND METHODS: In this Phase 1, multicenter, randomized, double-blind, placebo-controlled, parallel-group, ascending repeated dose study (NCT02803918), participants aged 10 and < 18 years were randomized 3:1 to receive once-daily lixisenatide in 2-week increments of 5,

…
MATERIALS AND METHODS: In this Phase 1, multicenter, randomized, double-blind, placebo-controlled, parallel-group, ascending repeated dose s …
Ventilatory control in myxedema and hypothyroidism.
Zwillich CW, Pierson DJ, Hofeldt FD, Lufkin EG, Weil JV. Zwillich CW, et al. N Engl J Med. 1975 Mar 27;292(13):662-5. doi: 10.1056/NEJM197503272921302. N Engl J Med. 1975. PMID: 1113761
A Randomized, Open-Label, Single-Dose Study to Assess Safety and Systemic Exposure of Triamcinolone Acetonide Extended-Release in Patients With Hip Osteoarthritis.
Kivitz A, Mehra P, Hanson P, Kwong L, Cinar A, Lufkin J, Kelley S. Kivitz A, et al. Rheumatol Ther. 2022 Apr;9(2):679-691. doi: 10.1007/s40744-022-00430-3. Epub 2022 Mar 8. Rheumatol Ther. 2022. PMID: 35258839 Free PMC article.
PK parameters included area under the concentration-time curve, total body drug clearance, maximum concentration (C(max)), mean residence time, half-life, and time to maximum concentration. RESULTS: Of 30 patients (TA-ER: n = 15; TAcs: n = 15) randomized and include …
PK parameters included area under the concentration-time curve, total body drug clearance, maximum concentration (C(max)), mean residence ti …
51 results